Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2006

View Archived Issues

Eltrombopag induces responses in hepatitis C patients with thrombocytopenia

Pasireotide shows potential in carcinoid tumors, acromegaly, Cushing's disease

Targeting LOX might help fight aggressive hypoxic tumors

Innogenetics and IBL Japan enter into license agreement in Alzheimer's field

Phase II evaluation of SP-01A begins second stage

Epigenetic therapy shows results in medulloblastoma in vitro experiments

GSK advances calcilytic compound from NPS collaboration

Diamyd Medical plans phase III study of Diamyd

Zonagen changes name to Repros Therapeutics

Vical's DNA vaccine protects against avian flu in animal studies

Smallpox drug candidate SIGA-246 enters phase I trials

Approvable letter for CIP-Isotretinoin

Enrollment completed in phase III trials of Nexavar in melanoma and liver cancer

FDA approves SPA for Puricase phase III trials

SPA agreement for phase III study of DG-031 for heart attack prevention

CancerVax stockholders approve merger with Micromet

XTL-2125 studied for chronic hepatitis C in new phase I trial

Encouraging phase I data for OGX-011 plus chemotherapy in NSCLC

Biogen Idec to acquire Conforma Therapeutics

Significant improvements in endpoints in integrated ambrisentan trials analysis

New higher dose formulations of Diovan HCT approved

CHMP recommends Seretide dosing for initial maintenance therapy

European approval for Tygacil

RotaTeq recommended for approval in Europe

Bioniche receives fast track designation for Urocidin

Recent patents impart new therapeutics for respiratory disorders

Novel agents for obesity and disorders of lipoprotein metabolism patented

New therapeutics for cancer covered in recent patent literature

Small alpha5beta1 integrin inhibitor reduces choroidal neovascularization in different animal models

Novel beta-tryptase inhibitor developed by Mochida

Novel antiatherothrombotic drug shows promise in preclinical studies

Preclinical data on antioxidant drugs for AMD reported by Othera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...